4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Receives Consensus Rating of “Moderate Buy” from Analysts

Shares of 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) have been assigned a consensus recommendation of “Moderate Buy” from the nine analysts that are covering the stock, Marketbeat Ratings reports. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and seven have issued a buy rating on the company. The average 1-year price target among brokerages that have issued a report on the stock in the last year is $32.7143.

A number of equities research analysts have commented on FDMT shares. Wall Street Zen raised 4D Molecular Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, March 21st. Weiss Ratings reiterated a “sell (d-)” rating on shares of 4D Molecular Therapeutics in a report on Wednesday, January 21st. Barclays began coverage on shares of 4D Molecular Therapeutics in a research note on Wednesday, January 28th. They issued an “overweight” rating and a $33.00 price objective for the company. Royal Bank Of Canada boosted their price objective on shares of 4D Molecular Therapeutics from $32.00 to $35.00 and gave the stock an “outperform” rating in a report on Thursday, March 19th. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $36.00 target price on shares of 4D Molecular Therapeutics in a report on Friday, March 20th.

Institutional Investors Weigh In On 4D Molecular Therapeutics

Institutional investors and hedge funds have recently modified their holdings of the company. AQR Capital Management LLC acquired a new position in 4D Molecular Therapeutics during the first quarter worth $46,000. Millennium Management LLC grew its holdings in 4D Molecular Therapeutics by 15.0% in the first quarter. Millennium Management LLC now owns 1,633,987 shares of the company’s stock valued at $5,278,000 after purchasing an additional 213,264 shares during the last quarter. Dynamic Technology Lab Private Ltd purchased a new position in shares of 4D Molecular Therapeutics in the first quarter valued at $39,000. American Century Companies Inc. increased its position in shares of 4D Molecular Therapeutics by 11.5% in the second quarter. American Century Companies Inc. now owns 48,810 shares of the company’s stock valued at $181,000 after buying an additional 5,026 shares in the last quarter. Finally, XTX Topco Ltd acquired a new position in shares of 4D Molecular Therapeutics during the 2nd quarter worth $292,000. Institutional investors and hedge funds own 99.27% of the company’s stock.

4D Molecular Therapeutics Trading Up 3.0%

Shares of FDMT stock opened at $10.18 on Friday. The stock has a 50 day simple moving average of $8.89 and a 200-day simple moving average of $9.18. The company has a market cap of $519.69 million, a price-to-earnings ratio of -4.21 and a beta of 2.99. 4D Molecular Therapeutics has a 12-month low of $2.23 and a 12-month high of $12.34.

4D Molecular Therapeutics (NASDAQ:FDMT) last posted its quarterly earnings results on Wednesday, March 18th. The company reported $0.43 earnings per share for the quarter, beating analysts’ consensus estimates of ($0.53) by $0.96. 4D Molecular Therapeutics had a negative return on equity of 31.75% and a negative net margin of 164.43%.The firm had revenue of $85.09 million for the quarter, compared to the consensus estimate of $30.86 million. On average, equities analysts forecast that 4D Molecular Therapeutics will post -2.84 earnings per share for the current fiscal year.

About 4D Molecular Therapeutics

4D Molecular Therapeutics, founded in 2015 and headquartered in Emeryville, California, is a clinical-stage biotechnology company focused on the development of targeted gene therapies for rare diseases. The company employs its proprietary Gene Expression AAV (GEA) platform to engineer novel adeno-associated virus (AAV) capsids with enhanced tissue selectivity and transduction efficiency. This platform aims to improve the precision and durability of gene delivery compared to traditional AAV approaches.

4D’s pipeline includes both preclinical and clinical-stage programs across multiple therapeutic areas.